Valente Manuela 4

What Happened Manuela Valente, Chief People Officer of SOPHiA GENETICS SA (SOPH), received equity awards on April 2, 2026: 71,869 restricted stock units (RSUs) and a derivative award covering 104,790 shares (an option-like grant). Both were granted at $0.00 per share (no cash exchanged at grant); combined the awards cover 176,659 shares. These are compensation awards (not open-market purchases or sales).

Key Details

• Transaction date: April 2, 2026; Form filed April 3, 2026 (appears timely).
• Grants: 71,869 RSUs (F1) and 104,790-share derivative award/options (F2); both shown at $0.00.
• Vesting (per footnotes): RSUs — 25% vest on April 2, 2027, remaining 75% vest in equal quarterly installments through April 2, 2030. Options — 25% vest on April 2, 2027, then vest in equal monthly installments through April 2, 2030.
• Shares owned after the grant were not specified in the provided excerpt.
• No 10b5-1 plan, tax-withholding, or late-filing flag noted in the provided data.

Context RSUs are contingent rights to receive ordinary shares upon vesting (i.e., they require continued service to convert to actual shares). The derivative award described functions like an option with a multi-year vesting schedule — these are standard compensation tools and do not indicate an immediate buy or sell by the insider. For retail investors, such awards mainly reflect executive compensation and retention, not necessarily a direct market sentiment signal.